Antiangiogenic therapy in ovarian cancer – for whom and when?

• Authors: Irem Bilgetekin , Bulent Cetin , Ahmet Ozet

Title variants

PL

Terapia antyangiogenna w raku jajnika – dla kogo ikiedy?

• Languages of publication: EN

Abstracts

EN

Tumor angiogenesis appears to be an important process in epithelial ovarian cancer development. Bevacizumab is a monoclonal antibody that can neutralize vascular endothelial growth factor, a promoter of the initiation phase of angiogenesis. First-line chemotherapy in combination with bevacizumab followed by maintenance bevacizumab demonstrated efficacy over chemotherapy alone in two phase III trials (Gynecologic Oncology Group, GOG 218 and ICON7); however, absolute progression-free survival benefit remains modest, with no demonstrated impact on overall survival. The addition of molecularly targeted agents to the treatment of women with recurrent and platinum-sensitive disease has been recently reported in the OCEANS study, which evaluated the benefit of adding bevacizumab to carboplatin and gemcitabine in women with platinum-sensitive recurrent disease. Bevacizumab-based therapy also extended progressionfree survival from 8 to 12 months. However, overall survival was not different between the two arms. In the Gynecologic Oncology Group 213 (GOG 213) trial, women with platinum-sensitive recurrent epithelial ovarian cancer were randomly assigned to medical treatment (carboplatin plus paclitaxel with or without bevacizumab). A significant improvement in progression-free survival (14 versus 10 months, respectively) was observed. A trend towards a significant improvement in overall survival, which was not statistically significant, was reported. In November 14, 2014, based on AURELIA findings, the Food and Drug Administration approved bevacizumab in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer. Ovarian cancer is a primary cancer against which these new agents are being tested. This review will describe the role of angiogenesis inhibitors in epithelial ovarian cancer.

PL

Angiogeneza nowotworowa wydaje się istotnym procesem w rozwoju raka jajnika. Bewacyzumab jest przeciwciałem monoklonalnym zdolnym do neutralizacji naczyniowo-śródbłonkowego czynnika wzrostu, promotora początkowej fazy angiogenezy. W dwóch badaniach klinicznych III fazy (Gynecologic Oncology Group – GOG 218 oraz ICON7) wykazano skuteczność chemioterapii pierwszego rzutu w skojarzeniu z bewacyzumabem i następowym leczeniem podtrzymującym bewacyzumabem w porównaniu z samą chemioterapią, jednak bezwzględne korzyści czasu wolnego bez progresji pozostają niewielkie, bez wpływu na przeżycie całkowite. W  badaniu OCEANS oceniono korzyści wynikające z  włączenia bewacyzumabu do terapii karboplatyną i gemcytabiną u kobiet z nawrotowym rakiem jajnika wrażliwym na platynę. Leczenie oparte na bewacyzumabie wydłużyło czas przeżycia bez progresji choroby z 8 do 12 miesięcy. Nie stwierdzono różnicy w odniesieniu do przeżycia całkowitego między dwiema grupami pacjentek. W badaniu klinicznym GOG 213 (Gynecologic Oncology Group 213) kobietom z nawrotowym rakiem jajnika wrażliwym na platynę losowo przypisywano rodzaj leczenia (karboplatynę plus paklitaksel z lub bez bewacyzumabu). Zaobserwowano istotną poprawę w zakresie przeżycia bez progresji choroby (odpowiednio 14 i 10 miesięcy). Odnotowano tendencję do poprawy w zakresie przeżycia ogólnego, jednak bez istotności statystycznej. W oparciu o wyniki badania AURELIA 14 listopada 2014 roku Agencja Żywności i Leków zatwierdziła bewacizumab w skojarzeniu z paklitakselem, pegylowaną liposomalną doksorubicyną lub topotekanem w leczeniu chorych z wrażliwym na platynę nawrotowym rakiem jajnika. Rak jajnika jest pierwszym nowotworem, wobec którego badane są te leki. W niniejszej pracy opisano rolę inhibitorów angiogenezy w nabłonkowym raku jajnika.

Keywords

EN

antiangiogenic agents; bevacizumab; ovarian cancer

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2017
• Volume: 15
• Issue: 1
• Pages: 78–85

Contributors

author

Irem Bilgetekin

• Department of Internal Medicine, Division of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

author

Bulent Cetin

• Department of Internal Medicine, Division of Medical Oncology, Recep Tayyip Erdogan University, Faculty of Medicine, Turkey

author

Ahmet Ozet

• Department of Internal Medicine, Division of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

References

• 1. International Agency for Research on Cancer: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/ Pages/bar_sex_pop_sel.aspx [cited 8 August 2014].
• 2. Ledermann JA, Raja FA, Fotopoulou C et al.; ESMO Guidelines Working Group: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi24–vi32.
• 3. Pujade-Lauraine E: How to approach patients in relapse. Ann Oncol 2012; 23 Suppl 10: x128–x131.
• 4. Burger RA, Brady MF, Bookman MA et al.; Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–2483.
• 5. Perren TJ, Swart AM, Pfisterer J et al.; ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–2496.
• 6. Aghajanian C, Blank SV, Goff BA et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039–2045.
• 7. Pujade-Lauraine E, Hilpert F, Weber B et al.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302–1308.
• 8. Coleman RL, Brady MF, Herzog TJ et al.: A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 213). Presented at the 46th Annual Meeting on Women’s Cancer of the Society of Gynecologic Oncology, Chicago, 2015.
• 9. Graybill W, Sood AK, Monk BJ et al.: State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol 2015; 138: 223–226.
• 10. Nagy JA, Dvorak HF: Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 2012; 29: 657–662.
• 11. Oza AM, Cook AD, Pfisterer J et al.: ICON7 trial investigators: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928–936.
• 12. National Comprehensive Cancer Network. Available from: http://www.nccn.org [cited: 21 November 2015].
• 13. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007; 107: 118–123.
• 14. Randall LM, Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117: 497–504.
• 15. McCann GA, Smith B, Backes FJ et al.: Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol 2012; 127: 362–366.
• 16. Coleman RL, Brady MF, Herzog TJ et al.: Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: a subgroup analysis of GOG0213. J Clin Oncol 2016; 34 (Suppl; abstr 5523).
• 17. Zhou Q, Guo P, Gallo JM: Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14: 1540–1549.
• 18. Burger RA, Sill MW, Monk BJ et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165–5171.
• 19. du Bois A, Floquet A, Kim JW et al.:Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374–3382.
• 20. du Bois A, Kristensen G, Ray-Coquard I et al.; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78–89.
• 21. Robson EJ, Ghatage P: AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011; 20: 297–304.
• 22. Eskander RN, Tewari KS: Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma – mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014; 132: 496–505.
• 23. Monk BJ, Poveda A, Vergote I et al.: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 799–808.
• 24. Amgen announces top-line secondary endpoint results of phase 3 trebananib TRINOVA-1 trial in patients with recurrent ovarian cancer. Available from: http://www.prnewswire.com/newsreleases/amgen-announces-top-line-secondary-endpoint-resultsof-phase-3-trebananib-trinova-1-trial-in-patients-with-recurrent-ovarian-cancer-281442761.html [cited 5 November 2014].
• 25. Ledermann JA, Embleton AC, Raja F et al.; ICON6 collaborators: Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 387: 1066–1074.

• Document Type: article